AI-designed monoclonal antibody ‘redirects’ the immune system
Drug Discovery World
MAY 31, 2023
Immuno-oncology company Aulos Bioscience has revealed interim results from an ongoing Phase I/II trial of monoclonal antibody AU-007 in solid tumours. AU-007 is a human IgG1 monoclonal antibody designed using artificial intelligence to harness the power of interleukin-2 (IL-2) to eradicate solid tumours.
Let's personalize your content